Attune Ensemble™ OTC, a First-of-Its-Kind Cancer Well-Being App, is Now Available for Free to Spanish-Speaking Patients
June 09, 2022 08:00 ET
|
Blue Note Therapeutics, Inc.
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics today announced plans to provide Spanish-speaking patients with immediate access to a new cancer-specific wellness app, attune...
OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-Related Anxiety and Depression Symptoms
May 31, 2022 08:00 ET
|
Blue Note Therapeutics, Inc.
SAN FRANCISCO, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, and...
Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune™ and DreAMLand™, Prescription Digital Therapeutics for Mental Well-Being in Cancer Patients
May 09, 2022 20:46 ET
|
Blue Note Therapeutics, Inc.
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into an exclusive licensing...